Dermatology Treatment and Research Center

Dallas, Texas 75320

3 studies enrolling now · 30 studies all time

What they study most

Actinic Keratosis, Alopecia, Alopecia Areata, Areata Alopecia, Atopic Dermatitis, Cutaneous Neurofibroma, Hair Diseases, Hidradenitis Suppurativa (HS), Hypotrichosis, Moderate to Severe Plaque Psoriasis, Neurofibromatosis 1, Non-segmental Vitiligo

Studies at this site

• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata — Recruiting now
• A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — Recruiting now
• A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Recruiting now
• A Study of Barzolvolimab in Patients With Prurigo Nodularis — Running, not enrolling
• Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) — Running, not enrolling
• A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. — Stopped early
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) — Running, not enrolling
• An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis — Stopped early
• NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) — Completed
• Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) — Completed
• A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. — Completed
• Light Treatment Effectiveness (LITE) Study — Completed
• Efficacy and Safety of ME3183 in Subjects With Moderate to Severe Plaque Psoriasis — Completed
• Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis — Completed
• Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea — Completed
• MSB11022 in Moderate to Severe Chronic Plaque Psoriasis — Completed
• A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) — Completed
• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis — Stopped early
• Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT) — Completed
• Efficacy, Safety, and Pharmacokinetic Profile of Etokimab (ANB020) in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Completed
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) — Completed
• Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed
• Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis — Stopped early
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis — Completed
• Tofacitinib Ointment For Chronic Plaque Psoriasis — Completed
• Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery — Completed